{"id":"NCT01836523","sponsor":"Novo Nordisk A/S","briefTitle":"The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes","officialTitle":"The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2013-04-22","resultsPosted":"2017-03-06","lastUpdate":"2017-03-06"},"enrollment":1398,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Liraglutide 0.6 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide 1.2 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide 1.8 mg + insulin","type":"EXPERIMENTAL"},{"label":"Liraglutide placebo 0.6 mg + insulin","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide placebo 1.2 mg + insulin","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide placebo 1.8 mg + insulin","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (Glycosylated Haemoglobin)","timeFrame":"Week 0, week 52","effectByArm":[{"arm":"Liraglutide 0.6 mg","deltaMin":-0.45,"sd":0.741},{"arm":"Liraglutide 1.2 mg","deltaMin":-0.5,"sd":0.767},{"arm":"Liraglutide 1.8 mg","deltaMin":-0.54,"sd":0.729},{"arm":"Placebo","deltaMin":-0.34,"sd":0.707}],"pValues":[{"comp":"OG002 vs OG003","p":null},{"comp":"OG001 vs OG003","p":null},{"comp":"OG000 vs OG003","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":182,"countries":["United States","Argentina","Australia","Belgium","Canada","Finland","France","Germany","Ireland","Israel","Netherlands","Norway","Poland","Russia","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["27506222","39717993","34463425"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":350},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Headache","Vomiting"]}}